Clinical Characteristics and Microbiology of Community-Acquired Pneumonia

April 3, 2017 updated by: Liu chao, Beijing Haidian Hospital

Clinical Characteristics and Microbiology of Community-Acquired Pneumonia: A Prospective Study

Community-Acquired Pneumonia has become common. Additionally, the mortality is high. But the epidemiology of pathogen is various in different areas, which is crucial for the key treatment. In addition, the risk factors of patients who died in 3 or 7 days in china is not clear, comparing with patients who died in 14 or 28 days or who survived.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100000
        • Recruiting
        • Beijing Haidian Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients with commnuity acquired pneumonia

Description

Inclusion Criteria:

  • Confirmed community acquired pneumonia
  • Age≥18 ys

Exclusion Criteria:

  • HIV infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Beijing Haidian Hospital
Cohort Study; pathogen; clinical features
Chinese PLA General Hospital
Cohort Study; pathogen; clinical features
Beijing Tsinghua Chang gung Hospital
Cohort Study; pathogen; clinical features

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the epidemiology of pathogen of community-acquired pneumonia in the three hospitals
Time Frame: confirmed as community-acquired pneumonia (2 weeks)
screen out the pathogen of community-acquired pneumonia
confirmed as community-acquired pneumonia (2 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
risk factors of patients who died in 3 or 7 days
Time Frame: in one week(3 days or 7days)
patients who die in 3 or 7 days
in one week(3 days or 7days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 11, 2017

Primary Completion (Anticipated)

April 1, 2019

Study Completion (Anticipated)

May 1, 2019

Study Registration Dates

First Submitted

March 22, 2017

First Submitted That Met QC Criteria

March 31, 2017

First Posted (Actual)

April 4, 2017

Study Record Updates

Last Update Posted (Actual)

April 5, 2017

Last Update Submitted That Met QC Criteria

April 3, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • Beijing Haidian Hospital

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Community-acquired Pneumonia

Clinical Trials on Cohort Study; pathogen; clinical features

3
Subscribe